Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms

Oncology Reports

Volumn 27, Issue 2, 2012, Pages 409-415

  Ferro, Matteo ^a   Giuberti, Gaia ^b   Zappavigna, Silvia ^b   Perdonà, Sisto ^c   Facchini, Gaetano ^c   Sperlongano, Pasquale ^b   Porto, Stefania ^b   Di Lorenzo, Giuseppe ^a   Buonerba, Carlo ^a   Abbruzzese, Alberto ^b   Altieri, Vincenzo ^a   Caraglia, Michele ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bladder cancer; Chondroitin sulphate; Gemcitabine; HT 1376; Mitomycin C

Indexed keywords

CASPASE 3; CASPASE 9; CHONDROITIN SULFATE; GEMCITABINE; MITOMYCIN C; UNCLASSIFIED DRUG; URACYST;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTRACELLULAR SIGNALING; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CHONDROITIN SULFATES; DEOXYCYTIDINE; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; MITOMYCIN; URINARY BLADDER NEOPLASMS;

EID: 84855754196     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1526     Document Type: Article

References (25)

1. Bodenstab W, Kaufman J and Parsons CL: Inactivation of antiadherence effect of bladder surface glycosaminoglycan by a complete urinary carcinogen (N-methyl-N-nitrosourea). J Urol 129: 200-201, 1983. (Pubitemid 13148094)
2. Di Stasi SM, Dutto L and Verri C: Electromotive drug administration® (EMDA) intravescicale con mitomicina-C nel trattamento dei tumori della vescica non-infiltranti la muscolare. Urologia 75: 214-220, 2008.
3. Kyker KD, Coffman J and Hurst RE: Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder. BMC Urol 23: 4, 2005.
4. Malmstrom PU: Intravesical therapy of superficial bladder cancer. Critical Rev Oncol Hematol 47: 109-123, 2003.
5. Bassi PF: BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg Oncol 11: 77-83, 2002.
6. Joudi FN and O'Donnell MA: Second-line intravesical therapy versus cystectomy for Bacille Calmette-Guérin (BCG) failure. Curr Opin Urol 14: 271-275, 2004. (Pubitemid 39141983)
7. Oosterlinck W, Lobel B and Jakse G: Guidelines on Bladder Cancer: The Commonly Advocated Doses for Mitomycin C are 2-40 mg. European Association of Urology Guidelines. Arhem, The Netherlands, EAU Healthcare Office, pp9, 2001.
8. Soloway MS: Introduction and overview of intravesical therapy for superficial bladder cancer. Urology 31 (Suppl 3): S5-S16, 1988.
9. Witjes JA and Hendricksen K: Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 53: 45-52, 2008. (Pubitemid 350167566)
10. Gårdmark T, Jahnson S, Wahlquist R, Wijkström H and Malmström PU: Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU Int 99: 817-820, 2007.
11. Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA and Madero R: A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52: 1398-1406, 2007. (Pubitemid 47449726)
12. Nissenkorn I, Herrod H and Soloway MS: Side effects associated with intravesical mitomycin. J Urol 126: 596-597, 1981. (Pubitemid 12245500)
13. Stadler WM, Kuzel T and Roth B: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15: 3394-3398, 1997. (Pubitemid 27485860)
14. Cozzi PJ, Bajorin DF and Tong W: Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 5: 2629-2637, 1999. (Pubitemid 29437351)
15. Chou J and Chou TC: Manual and Software, Biosoft, Cambridge, UK, 1987.
16. Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V and Del Prete S: Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 28: 543-548, 2010.
17. Volpi N, Bolognani L, Conte A and Petrini M: Effects of chondroitin sulfates with different structures on leukemia cells: U-937 cell proliferation and differentiation. Leuk Res 17: 789-798, 1993. (Pubitemid 23286842)
18. Caraglia M, Marra M, Budillon A, Meo G, Ricciardiello F, Bismuto E, Brachelente G, Francini G, Giordano A, Correale P and Abbruzzese A: Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation. Cancer Biol Ther 4: 1159-1167, 2005. (Pubitemid 41598574)
19. Pan CW, Shen ZJ, Wu TT, Tang XY, Wang M, Sun J and Shao Y: Cell adhesion to fibronectin induces mitomycin C resistance in bladder cancer cells. BJU Int 104: 1774-1779, 2009.
20. Ma Y, Yu WD, Trump DL and Johnson CS: 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 116: 3294-3303, 2010.
21. Sun HZ, Wu SF and Tu ZH: Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity. Cell Res 11: 107-115, 2001. (Pubitemid 33677216)
22. Weigel PH and Yik JH: Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochim Biophys Acta 1572: 341-363, 2002. (Pubitemid 35246354)
23. Harris EN, Weigel JA and Weigel PH: Endocytic function, glycosaminoglycan specificity, and antibody sensitivity of the recombinant human 190-kDa hyaluronan receptor for endocytosis (HARE). J Biol Chem 279: 36201-36209, 2004. (Pubitemid 39128955)
24. Bapat SA: Human ovarian cancer stem cells. Reproduction 140: 33-41, 2010.
25. Serafino A, Zonfrillo M, Andreola F, Psaila R, Mercuri L, Moroni N, Renier D, Campisi M, Secchieri C, Pierimarchi P: CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. Curr Cancer Drug Targets 11: 572-585, 2011.